Read More About Medicines in Development for Diabetes
Medicines in Development for Diabetes
America’s biopharmaceutical research companies currently are developing 180 innovative new medicines to help the nearly 400 million people who have diabetes worldwide. These medicines in development – all either in clinical trials or under review by the Food and Drug Administration (FDA) – include 30 for type 1 diabetes, 100 for type 2 and 52 for diabetes-related conditions, according to a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA).
In the United States, nearly 26 million patients are affected by diabetes. The disease is one of the leading killers of Americans and the epidemic is quickly escalating. According to theCenters for Disease Control and Prevention (CDC), the prevalence of diabetes among U.S. adults grew by 45 percent over the past 20 years. Today, one in 10 American adults has diabetes and as many as one in three could face the disease by 2050 if the current trends continue.
“Dedicated researchers in the biopharmaceutical sector, working hand-in-hand with others in the medical innovation ecosystem, are striving to meet the global challenge of diabetes by developing new innovative treatment options,” said PhRMA President and CEO John J. Castellani. “The nearly 200 medicines in development today offer great hope that together we can ease the tremendous burden of diabetes on patients, public health and economies around the world.”
- 2014 Report: Medicines in Development for Diabetes (PDF)
- Overview: Biopharmaceutical Research Companies Are Developing More Than 180 Medicines to Treat Diabetes and Related Conditions